_edited.png)
DEA Submits Final Brief in Cannabis Rescheduling Hearing
Fast Facts
Who / Where: Drug Enforcement Administration (DEA) and rescheduling opponents, Washington, D.C.
What changed: Final briefs were filed in the administrative hearing regarding the proposal to move cannabis from Schedule I to Schedule III.
Effective / Key date: November 9, 2026
Status: Awaiting the administrative law judge's recommendation to DEA Administrator Terry Cole.
DMV impact: Shapes federal policy alignment with state-regulated medical and adult-use markets across Maryland, Virginia, and Washington, D.C.
The bottom line: With the Drug Enforcement Administration and rescheduling opponents filing final briefs in November 2026 on shifting cannabis from Schedule I to Schedule III, the administrative hearing nears a critical recommendation that could redefine cannabis laws and delivery regulations.
The evolving landscape of American drug policy has reached an encouraging milestone. As reported by Marijuana Moment, the Drug Enforcement Administration and its opponents have delivered what appear to be the final briefs in a significant administrative hearing. This process focuses on the proposal to reclassify cannabis from the highly restrictive Schedule I to the more lenient Schedule III under the Controlled Substances Act. Once the presiding administrative law judge reviews these closing arguments, the vital recommendation will be conveyed to DEA Administrator Terry Cole, laying the groundwork for a substantial shift in federal policy.
How Will the DEA Rescheduling Hearing Impact Maryland Cannabis Laws?
The potential federal rescheduling won't instantly transform local laws, but its implications for state-regulated programs are significant, especially for Maryland's growing medical cannabis framework and adult-use retail market. Currently, state-licensed operators grapple with heavy tax burdens stemming from Section 280E of the Internal Revenue Code, which prevents standard business deductions for establishments dealing in Schedule I or II substances. Transitioning cannabis to Schedule III could alleviate these burdens, allowing dispensaries, cultivators, and delivery services across the region to access much-needed capital.
Moreover, state regulators are closely monitoring how federal agencies handle compliance with state oversight. Maryland has crafted a detailed regulatory framework encompassing seed-to-sale tracking, facility inspections, and lab testing. By recognizing cannabis under Schedule III, there’s potential for creating a bridge toward standardized pharmaceutical research and enhanced interstate commerce frameworks. Consumers trying to navigate Maryland’s cannabis laws or checking local medical card limits should remember that, while state-level possession and purchase rules still apply, shifts in federal policy heavily influence access to banking, research funding, and merchant services for licensed operators.
What's the Impact for DC, Maryland, and Virginia Residents?
For consumers and patients in the District of Columbia, Maryland, and Virginia, federal administrative proceedings may feel remote from their daily interactions at local dispensaries or during delivery meetups. Yet, the outcomes from these hearings ripple into market stability, ensuring banking security for local couriers and legitimizing state medical programs. In Virginia, legislative delays in commercial retail sales coincide with established gifting and possession allowances. Here, federal reforms provide fresh momentum for state lawmakers who are pushing for clear licensing and transportation frameworks. In Washington, D.C., consumers navigating the unique grey-market initiatives keep an eye on how federal scheduling impacts local autonomy and enforcement priorities.
As state agencies refine marijuana delivery regulations and hemp compliance rules—like the recent guidance from Maryland regulators on hemp testing laboratories—federal alignment creates a more stable backdrop for legal cannabis transport. Whether relying on medical marijuana deliveries in Maryland or engaging in legal adult-use markets, the rescheduling of cannabis is a step toward dismantling outdated prohibition barriers that have historically muddied supply chains and merchant processing.
Regulatory Aspect | Current Schedule I Status | Proposed Schedule III Status | Impact on DMV Markets |
|---|---|---|---|
Tax Treatment (280E) | No standard business deductions allowed | Deductions permitted for ordinary business expenses | Lowers operational costs for state-licensed dispensaries and delivery services |
Medical Recognition | No accepted medical use recognized federally | Recognized medical utility with FDA-approved pathways | Strengthens state medical cannabis programs and veteran access initiatives |
Banking & Finance | High risk; limited institutional banking access | Expanded access to traditional financial services and merchant processing | Improves safety for cash-heavy cannabis courier operations and retail stores |
Scientific Research | Strict barriers and federal quotas | Streamlined research protocols and clinical trials | Accelerates clinical data on cannabis efficacy and product safety |
What Are the Next Steps in the Federal Rescheduling Process?
The administrative law judge now faces the task of thoroughly evaluating the extensive evidence, witness testimonies, and final written briefs submitted by the DEA and opposing parties. Upon completion of this review, the judge will produce a formal recommended decision for DEA Administrator Terry Cole. This recommendation, while not final, serves as a crucial and influential step before the agency processes a final ruling to lower cannabis to Schedule III.
Experts in drug policy reform anticipate that legal challenges and public comments will likely follow any final agency decision, indicating that the complete transition could stretch on for months. In the meantime, state legislatures—including those in the DMV region—continue adapting their statutory frameworks independently. State regulators are actively addressing parallel administrative updates, as seen with Florida's proposed regulations on medical cannabis delivery devices and Illinois' ongoing litigation regarding hemp-derived THC constraints, which exemplify that state oversight remains proactive despite the slower federal pace.
Does moving cannabis to Schedule III make recreational weed federally legal?
A shift to Schedule III does not legalize recreational cannabis use nationwide; adult-use legality is still determined by individual state laws. Instead, this reclassification acknowledges accepted medical uses, reducing federal barriers related to research, taxation, and business operations for state-compliant medical programs.
How will federal rescheduling affect cannabis delivery laws?
Cannabis delivery laws and courier regulations are established at the state and local level, not directly dictated by federal scheduling. However, easing federal restrictions can improve banking access and availability of capital for licensed delivery operators, indirectly supporting the growth of safer and more robust supply chains.
What happens to Section 280E if cannabis is rescheduled?
Internal Revenue Code Section 280E currently bars businesses dealing in Schedule I or II substances from claiming standard business deductions. Rescheduling cannabis to Schedule III would effectively lift this prohibition, permitting state-licensed cannabis businesses to deduct normal operational expenses, such as rent, payroll, and marketing.
Can military veterans access medical cannabis through federal programs under Schedule III?
Federal rescheduling paves the way for enhanced clinical research and potential discussions regarding Department of Veterans Affairs policies. However, active legislative efforts—like recent measures in Massachusetts allowing veterans access to medical cannabis without standard doctor recommendations—are driving immediate practical changes.
When will the final decision on cannabis rescheduling take effect?
There is no set timeline for concluding the DEA's administrative process. The administrative law judge must provide a recommendation before the agency can draft and publish a final rule, which may then undergo legal review.
Our Take: Navigating the Intersection of Federal Policy and Local Markets
At Bud Lords, we observe that while the machinery of D.C. moves at its characteristic crawl, the DEA rescheduling hearings signify a monumental shift in ideology. For years, state-licensed operators in Maryland and nearby jurisdictions have meticulously crafted compliance ecosystems while existing under federal prohibition's shadow. Schedule III won't magically unify mismatched state rules or replace local delivery compliance, but it officially ends the federal rejection of cannabis's medical utility. As this process progresses toward a conclusion, consumers and entrepreneurs in the DMV should stay attuned to how forthcoming federal tax relief and research validation will ripple through local dispensaries and delivery networks.
Have a cannabis story, local update, or strain you want our newsroom to cover? Request a story →
Written by Market Maven AI
Bud Lords AI Cannabis News Writer
Business and finance expert voice. Covers dispensary news, MSO developments, market trends, and financial analysis with industry insight.
Expertise: business · finance
This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.
Comments